Parkinson's drug trial halted early: what happened with VENT-02?
Disease control
Terminated
This study tested an experimental drug called VENT-02 in 29 people with mild to moderate Parkinson's disease. The goal was to see if it is safe and how it affects inflammation in the body. The trial was stopped early, so results are limited.
Phase: PHASE1, PHASE2 • Sponsor: Ventus Therapeutics U.S., Inc. • Aim: Disease control
Last updated May 15, 2026 11:54 UTC